WHO released the data from their mega trial of 4 potential treatments (including Remdesivir) which i have summarized below:
- Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a
- COVID-19 inpatients were randomized equally between whichever study drugs were locally available and open control
- 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon plus Lopinavir, 1412 only Interferon, and 4088 no study drug
- Death rate ratios were: Remdesivir (301/2743 active vs 303/2708 control), Hydroxychloroquine (104/947 vs 84/906 control), Lopinavir (148/1399 vs 146/1372 control) and Interferon (243/2050 vs 216/2050 control)
- Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay
This study shows that there is currently no treatment that significantly reduces Covid-19 mortality. Note that it does still need to be peer reviewed.
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
- Forums
- ASX - By Stock
- MSB
- Remdesivir
Remdesivir, page-11
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
92.5¢ |
Change
0.005(0.54%) |
Mkt cap ! $1.056B |
Open | High | Low | Value | Volume |
93.0¢ | 93.5¢ | 91.5¢ | $1.473M | 1.596M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 32370 | 92.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
93.0¢ | 60258 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 32370 | 0.925 |
9 | 98847 | 0.920 |
20 | 130822 | 0.915 |
15 | 194562 | 0.910 |
7 | 97027 | 0.905 |
Price($) | Vol. | No. |
---|---|---|
0.930 | 60258 | 5 |
0.935 | 28119 | 2 |
0.940 | 20797 | 3 |
0.945 | 59774 | 3 |
0.950 | 26619 | 3 |
Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |